Behavioral and Self-Report Cognitive Impairment Differences between Fast-Acting, Standard, and Placebo Cannabis Edibles

Abstract

Rationale: Fast-acting edible cannabis products are marketed as producing quicker effects than standard edibles, but whether faster absorption translates into earlier cognitive impairment due to cannabis intoxication is unclear. Objectives : We compared fast-acting, standard, and placebo edibles in a double-blind, within-subject crossover study of 20 adult individuals who frequently use cannabis.

Methods: Participants completed three mobile laboratory sessions after ingesting either a fast-acting, standard, or placebo cannabis edible and were assessed repeatedly over 270 minutes using the DRUID impairment app and selected self-report items from the Subjective High Assessment Scale (SHAS).

Results: Mixed-effects models showed limited evidence that the fast-acting edible produced significantly earlier impairment than the standard edible. Behavioral impairment showed no clear pattern over time. Self-reported effects were more consistent across both active edibles, with elevations in clumsiness, distorted time perception, and other subjective impairment outcomes relative to placebo. However, the fast-acting and standard edibles generally showed similar time courses, with little evidence of a meaningful advantage for the fast-acting formulation.

Conclusions: Both active edibles produced several hours of subjective impairment, but the fast-acting product did not consistently yield significantly earlier cognitive effects than the standard edible.